Blueprint Medicines Corp (NAS:BPMC)
$ 96.53 -1.09 (-1.12%) Market Cap: 6.13 Bil Enterprise Value: 5.94 Bil PE Ratio: 0 PB Ratio: 19.54 GF Score: 81/100

Q2 2023 Blueprint Medicines Corp Earnings Call Transcript

Aug 02, 2023 / 12:00PM GMT
Release Date Price: $54.3 (-15.34%)
Operator

Good morning, ladies and gentlemen. My name is Glenn. I'll be your conference operator today. At this time, I would like to welcome everyone to the Blueprint Medicines' Second Quarter 2023 Financial Results Conference Call. (Operator Instructions)

I will now turn it to Jenna Cohen, Vice President of Investor Relations to begin.

Jenna Cohen
Blueprint Medicines Corporation - Senior Director & Head of IR

Thank you, Glenn. Good morning, everyone, and welcome to Blueprint Medicines' second quarter 2023 financial and operating results conference call. This morning we issued a press release which outlines the topics we plan to discuss today. You can access the press release as well as the slides that we'll be reviewing today by going to the Investors section of our website at www.blueprintmedicines.com.

Joining me today are Kate Haviland, Chief Executive Officer; Philina Lee, Chief Commercial Officer; Fouad Namouni, President, Research & Development; and Mike

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot